This Article Full Text Full Text (PDF) All Versions of this Article: jhc.4C6561.2005v1 53/10/1181    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bord, S. Articles by Compston, J. E. Search for Related Content PubMed PubMed Citation Articles by Bord, S. Articles by Compston, J. E. Social Bookmarking                      What's this?

Characterization of Osteocrin Expression in Human Bone

Sharyn Bord, Deborah C. Ireland, Pierre Moffatt, Gethin P. Thomas and Juliet E. Compston

Cambridge University School of Clinical Medicine, Addenbrooke's Hospital, Cambridge, UK (SB,DCI,JEC), and Phenogene Therapeutics Inc., Montreal, Quebec, Canada (PM,GPT)

Correspondence to: Professor Juliet Compston, University of Cambridge School of Clinical Medicine, Addenbrooke's Hospital, Box 157, Cambridge, CB2 2QQ, UK. E-mail: jec1001{at}cam.ac.uk

Osteocrin (Ostn), a bone-active molecule, has been shown in animals to be highly expressed in cells of the osteoblast lineage. We have characterized this protein in human cultured primary human osteoblasts, in developing human neonatal bone, and in iliac crest bone biopsies from adult women. In vivo, Ostn expression was localized in developing human neonatal rib bone, with intense immunoreactivity in osteoblasts on bone-forming surfaces, in newly incorporated osteocytes, and in some late hypertrophic chondrocytes. In adult bone, Ostn expression was specifically localized to osteoblasts and young osteocytes at bone-forming sites. In vitro, Ostn expression decreased time dependently (p<0.02) in osteoblasts cultured for 2, 3, and 6 days. Expression was further decreased in cultures containing 200 nM hydrocortisone by 1.5-, 2.3-, and 3.1-fold (p<0.05) at the same time points. In contrast, alkaline phosphatase expression increased with osteoblast differentiation (p<0.05). Low-dose estradiol decreased Ostn expression time dependently (p<0.05), whereas Ostn expression in cultures treated with high-dose estradiol was not significantly changed. These results demonstrate that Ostn is expressed in human skeletal tissue, particularly in osteoblasts in developing bone and at sites of bone remodeling, suggesting a role in bone formation. Thus, Ostn provides a marker of osteoblast lineage cells and appears to correlate with osteoblast activity. (J Histochem Cytochem 53:1181–1187, 2005)

Key Words: osteocrin • osteoblasts • osteocytes • human bone formation

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				P. Moffatt, G. Thomas, K. Sellin, M.-C. Bessette, F. Lafreniere, O. Akhouayri, R. St-Arnaud, and C. Lanctot Osteocrin Is a Specific Ligand of the Natriuretic Peptide Clearance Receptor That Modulates Bone Growth J. Biol. Chem., December 14, 2007; 282(50): 36454 - 36462. [Abstract] [Full Text] [PDF]

Guidelines | Subscriptions | About | exPRESS - Current - Archive | Business Information | Contact

The Journal of Histochemistry & Cytochemistry is owned, published, and licensed by The Histochemical Society © 2005